QQQ $ 442.84 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.61 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 216.28 $ -2.45 (-1.12 %)
$ 0.0562
-- x --
-- x --
-- - --
$ 0.00 - $ 0.09
30,552
na
na
$ 0.49
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tryp-therapeutics-set-to-finalize-merger-with-exopharm-announces-trading-halt-ahead-of-asx-listing

Tryp Therapeutics finalizes merger with Exopharm, prepares for ASX listing with strategic shareholder benefits. Explore merger ...

 psyched-100m-for-mdma-therapy-va-funds-2024-watchlist-reform-updates-and-more

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

 tryp-therapeutics-explores-psilocybins-potential-in-new-trials-to-treat-ibs-and-fibromyalgia

Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milest...

 psyched-ndaa-amendments-blocked-national-practitioners-network-marijuana-in-jackie-kennedys-garden-and-more

GOP-Controlled House Committee Blocks All Cannabis & Psychedelics Amendments To Defense Bill: Now, No Floor Vote

 psilocybin-for-ibs-gets-fda-nod-to-begin-clinical-trials-at-mass-general-hospital

Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the compa...

 silo-pharmas-new-ketamine-implant-for-fibromyalgia-and-chronic-pain-is-in-the-making

Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to st...

 tryp-submits-ind-application-to-fda-for-clinical-trial-of-psilocybin-assisted-psychotherapy-in-patients-with-ibs

Tryp Therapeutics, Inc. (OTCQB: TRYPF) (CSE:TRYP) has submitted an Investigational New Drug application to the U.S.

 psyched-oregon-and-colorado-regulations-mindmed-ceo-discusses-lsd-therapy-mia-khalifa-enters-market--more

Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued

 tryp-therapeutics-secures-16m-via-oversubscribed-private-placement

Tryp Therapeutics Inc. (OTCQB: TRYPF) (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infu...

 exclusive-in-reinventing-mental-health--next-gen-psychedelics-access-and-clinical-data-are-key

Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutioni...

 therapists-at-mass-general-hospital-prepared-to-assist-ibs-patients-with-psilocybin-therapy

Psychotherapists at the Massachusetts General Hospital (MGH) have undergone training by lead business Fluence toward participat...

 what-to-expect-from-the-benzinga-psychedelics-capital-conference-the-must-attend-event-for-this-emerging-industry

The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those ...

 psyched-ny-discusses-regulations-mdma-for-ptsd-aims-for-legalization-shrooms-for-eating-disorders--more

Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully l...

 treating-binge-eating-disorder-with-magic-mushrooms-phase-2-clinical-trial-gets-thumbs-up

Clinical-stage psychedelics biotech Tryp Therapeutics, Inc.

 business--academia-join-forces-to-study-magic-mushroom-therapy-for-ibs-patients

Psychedelics company Tryp Therapeutics Inc.

 this-psychedelics-company-is-patenting-its-psilocin-and-psilocybin-delivery-route

The World Intellectual Property Organization (WIPO) has published clinical-stage biopharma Tryp Therapeutics Inc. (OTCQB: TRYPF...

 is-psilocybin-therapy-a-potential-treatment-for-fibromyalgia--binge-eating-disorder

Clinical-stage developer of psychedelic compounds Tryp Therapeutics Inc. (OTCQB: TRYPF) filed two provisional patent applicatio...

 psychedelics-companies-share-corporate-updates-numinus-delix-tryp-and-small-pharma

Numinus Updates On New Acquisition’s Integration And Provides Client Financing Options

 psyched-elon-musk-tweets-about-psychedelics-numinus-acquires-novamind-colorado-gov-signs-mdma-legalization-bill

Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelic...

 clinical-trials-of-psilocybin-treatment-for-overeating-disorder-are-ready-heres-what-results-show-so-far

Tryp Therapeutics Inc. (OTCQB: TRYPF) is a clinical-stage biotech company focused on developing psilocybin-based compounds for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION